AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9862579 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 5 LOH in adenomas
Number of subjects: 27
Study 9862579 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 5 LOH in early-stage cancers
Number of subjects: 27
Study 9862579 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 5 LOH in advanced-stage cancers
Number of subjects: 27
Study 7896982 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychodynamic-interpersonal treatment
Number of subjects: 39
Study 7896982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 39
Study 1698333 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diet program for preterm infants
Number of subjects: 0
Study 582549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium medication (dosage: 24 mval/d to 36 mval/d)
Number of subjects: 24
Study 582549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30674311 — intervention group
Group type: EXPERIMENTAL
Intervention: PACIC‐5A questionnaire
Number of subjects: 117
Study 28397569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (FLU‐IVIG)
Number of subjects: 0
Study 28397569 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 28397569 — intervention group
Group type: EXPERIMENTAL
Intervention: Misclassification and collapsing categories
Number of subjects: 0
Study 28397569 — intervention group
Group type: EXPERIMENTAL
Intervention: Collapsing categories with no treatment effect
Number of subjects: 0
Study 25849049 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 50
Study 25849049 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 50
Study 23981319 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral osteopathy
Number of subjects: 31
Study 23981319 — intervention group
Group type: COMPARATOR
Intervention: Placebo manipulations
Number of subjects: 31
Study 21721148 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Waiguan points (TE5) on left hands for 20 minutes
Number of subjects: 24
Study 21721148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 24
Study 19782419 — intervention group
Group type: COMPARATOR
Intervention: CEOP
Number of subjects: 75
Study 19782419 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP plus semustine
Number of subjects: 75
Study 19782419 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index (low risk, intermediate risk, high risk)
Number of subjects: 75
Study 16877719 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 1: Bolus FU in two 5-day cycles every 28 days before and after radiotherapy plus FU via protracted venous infusion (PVI) 225 mg/m2/d during XRT
Number of subjects: 1917
Study 16877719 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 2: PVI-only arm, with PVI 42 days before and 56 days after XRT + PVI
Number of subjects: 1917
Study 16877719 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 3: Bolus-only arm, with bolus FU + leucovorin (LV) in two 5-day cycles before and after XRT, plus bolus FU + LV
Number of subjects: 1917
Study 12741422 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 40
Study 12741422 — intervention group
Group type: COMPARATOR
Intervention: Washed wound drainage transfusion
Number of subjects: 40
Study 10971308 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg PSC (valspodar) as an i.v. infusion over 2 h
Number of subjects: 18
Study 10971308 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine HCl (7.5 mg) infused over 2 h
Number of subjects: 18
Study 10971308 — intervention group
Group type: COMPARATOR
Intervention: PSC alone
Number of subjects: 18
Study 8839839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HY)
Number of subjects: 105
Study 8839839 — intervention group
Group type: COMPARATOR
Intervention: VP16
Number of subjects: 105
Study 1477492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive individual training
Number of subjects: 14
Study 1477492 — intervention group
Group type: COMPARATOR
Intervention: Less intensive group training
Number of subjects: 14
Study 6384636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 1% eyedrops
Number of subjects: 0
Study 6384636 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 0.17% eyedrops
Number of subjects: 0
Study 6384636 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 0.35% eyedrops
Number of subjects: 0
Study 6384636 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 0.5% eyedrops
Number of subjects: 0
Study 6384636 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 0.72% eyedrops
Number of subjects: 0
Study 6384636 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 1.0% eyedrops
Number of subjects: 0
Study 29756496 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage procedure
Number of subjects: 180
Study 29756496 — intervention group
Group type: COMPARATOR
Intervention: 2-stage procedure
Number of subjects: 180
Study 29909855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) for 1 month, n=29
Number of subjects: 50
Study 29909855 — intervention group
Group type: COMPARATOR
Intervention: Control group (C), n=21
Number of subjects: 50
Study 26950098 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-instruction (booklet with self-instructions and e-mail contact with a therapist)
Number of subjects: 100
Study 26950098 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study 24140172 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-min isokinetic all-out test at 60 rpm
Number of subjects: 14
Study 24140172 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-min isokinetic all-out test at 100 rpm
Number of subjects: 14
Study 24140172 — intervention group
Group type: COMPARATOR
Intervention: Incremental ramp testing
Number of subjects: 14
Study 22370314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg daily)
Number of subjects: 313
Study 22370314 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and Cisplatin (GP) chemotherapy (gemcitabine 1,250 mg/m2 on days 1 and 8; cisplatin 80 mg/m2 on day 1 every 3 weeks, for up to nine courses)
Number of subjects: 313
Study 19559965 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with CRS
Number of subjects: 40
Study 19559965 — intervention group
Group type: COMPARATOR
Intervention: Children without CRS
Number of subjects: 40
Study 19559965 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with severe CRS
Number of subjects: 40
Study 17623745 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 33
Study 15896183 — intervention group
Group type: COMPARATOR
Intervention: Zinc supplementation
Number of subjects: 392
Study 15896183 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A supplementation
Number of subjects: 392
Study 15896183 — intervention group
Group type: COMPARATOR
Intervention: Combined zinc and vitamin A supplementation
Number of subjects: 392
Study 15896183 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 392
Study 12100939 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 89
Study 12100939 — intervention group
Group type: COMPARATOR
Intervention: Lanolin hand cream
Number of subjects: 89
Study 12100939 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 89
Study 11213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking education in pregnancy
Number of subjects: 1823
Study 11213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking behaviour
Number of subjects: 1823
Study 11213007 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative classifications of smoking behaviour
Number of subjects: 1823
Study 9137929 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole + Propranolol (40 mg)
Number of subjects: 7
Study 9137929 — intervention group
Group type: COMPARATOR
Intervention: Carbimazole + Placebo
Number of subjects: 7
Study 7966415 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate predictive models using tumor size, patient age, S phase, and PgR as independent predictors.
Number of subjects: 11964
Study 7966415 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of prognostic indicator information to tumor size.
Number of subjects: 11964
Study 7966415 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models.
Number of subjects: 11964
Study 3298419 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% reduction of cis(z)‐flupenthixol decanoate
Number of subjects: 18
Study 3298419 — intervention group
Group type: COMPARATOR
Intervention: Pre-trial dosage of cis(z)‐flupenthixol decanoate
Number of subjects: 18
Study 29890982 — intervention group
Group type: EXPERIMENTAL
Intervention: PPFP intervention package
Number of subjects: 0
Study 29890982 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 27209291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lusutrombopag (14-day once-daily dosing)
Number of subjects: 78
Study 27209291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lusutrombopag
Number of subjects: 78
Study 25311610 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol capsule
Number of subjects: 50
Study 25311610 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 50
Study 23602776 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice-daily
Number of subjects: 15526
Study 23602776 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice-daily
Number of subjects: 15526
Study 23602776 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rivaroxaban group
Number of subjects: 15526
Study 23602776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15526
Study 20950174 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exploration of a virtual forest (nature condition)
Number of subjects: 22
Study 20950174 — intervention group
Group type: COMPARATOR
Intervention: Slide show in VR (control condition)
Number of subjects: 22
Study 18812128 — intervention group
Group type: EXPERIMENTAL
Intervention: Monarch III with D cartridge, direct implantation
Number of subjects: 100
Study 18812128 — intervention group
Group type: EXPERIMENTAL
Intervention: Monarch III with D cartridge, wound-assisted implantation
Number of subjects: 100
Study 18812128 — intervention group
Group type: EXPERIMENTAL
Intervention: Monarch II with C cartridge, direct implantation
Number of subjects: 100
Study 18812128 — intervention group
Group type: EXPERIMENTAL
Intervention: Monarch II with C cartridge, wound-assisted implantation
Number of subjects: 100
Study 16636364 — intervention group
Group type: EXPERIMENTAL
Intervention: Horsechestnut seed extract therapy combined with conventional therapy
Number of subjects: 54
Study 16636364 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 54
Study 12792557 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 298
Study 12792557 — intervention group
Group type: COMPARATOR
Intervention: No Acupuncture
Number of subjects: 298
Study 12792557 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 298
Study 10977025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with insulin alone or with sulfonylurea (n = 75)
Number of subjects: 153
Study 10977025 — intervention group
Group type: COMPARATOR
Intervention: Standard once-daily insulin injection (n = 78)
Number of subjects: 153
Study 10977025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (n = 66)
Number of subjects: 153
Study 10977025 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n = 70)
Number of subjects: 153
Study 10977025 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of 104 patients (STD, n = 53; INT, n = 51)
Number of subjects: 153
Study 10977025 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal LV ejection fraction at baseline
Number of subjects: 153
Study 8841900 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic tetracycline (250 mg qds for 14 days)
Number of subjects: 38
Study 8841900 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman flap surgery with adjunctive tetracycline
Number of subjects: 38
Study 8841900 — intervention group
Group type: COMPARATOR
Intervention: Modified Widman flap surgery with placebo
Number of subjects: 38
Study 1632100 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gown
Number of subjects: 87
Study 1632100 — intervention group
Group type: COMPARATOR
Intervention: Standard drape
Number of subjects: 87
Study 29695594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 3, 30, or 60 mg every 12 weeks, or 60 mg every 4 weeks
Number of subjects: 232
Study 29695594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (all doses)
Number of subjects: 232
Study 29695594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 232
Study 29695594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 26847290 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 177
Study 26847290 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 177
Study 26847290 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 177
Study 25004803 — intervention group
Group type: EXPERIMENTAL
Intervention: Interreality paradigm (Experimental Group, EG) for 5 weeks
Number of subjects: 121
Study 25004803 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) (Control Group, CG) for 5 weeks
Number of subjects: 121
Study 22872468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral peptone load (10 g)
Number of subjects: 72
Study 22872468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium load (1 g)
Number of subjects: 72
Study 22872468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral peptone load with aluminum hydroxide (AH)
Number of subjects: 72
Study 20688261 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (listening to chosen music for 30 minutes per week for 4 weeks)
Number of subjects: 42
Study 20688261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 42
Study 18096650 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement training (PT-M group)
Number of subjects: 39
Study 18096650 — intervention group
Group type: COMPARATOR
Intervention: Social training (PT-S group)
Number of subjects: 39
Study 18096650 — intervention group
Group type: COMPARATOR
Intervention: Full-term infants (FT-S group)
Number of subjects: 39
Study 16445598 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate buffer
Number of subjects: 54
Study 16445598 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine buffer
Number of subjects: 54
Study 12913042 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire with opinion leaders' endorsement
Number of subjects: 395
Study 12913042 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire without endorsement (Control)
Number of subjects: 395
Study 10997952 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (25 g CrH2O)
Number of subjects: 24
Study 10997952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9075670 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg terlipressin
Number of subjects: 23
Study 9075670 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg terlipressin
Number of subjects: 23
Study 9075670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8368169 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of nebulized solution of non-bronchodilator (+) isoprenaline
Number of subjects: 10
Study 8368169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 3758469 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT + AMI (50 mg/5 mg)
Number of subjects: 10
Study 3758469 — intervention group
Group type: COMPARATOR
Intervention: F + TRI (40 mg/50 mg)
Number of subjects: 10
Study 29722590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 capsule (5,000 IU/day)
Number of subjects: 35
Study 29722590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 26684633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular TNF blockers
Number of subjects: 82
Study 26684633 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 82
Study 24857299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban early treatment group (administered routinely at ≥ 4 hours prior to angiography)
Number of subjects: 104
Study 24857299 — intervention group
Group type: COMPARATOR
Intervention: Control group (tirofiban provisional administered during or after angiography)
Number of subjects: 104
Study 22672173 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART card
Number of subjects: 125
Study 22672173 — intervention group
Group type: COMPARATOR
Intervention: Northern Territory card
Number of subjects: 125
Study 22672173 — intervention group
Group type: COMPARATOR
Intervention: Doctors
Number of subjects: 125
Study 22672173 — intervention group
Group type: COMPARATOR
Intervention: All professional groups
Number of subjects: 125
Study 22672173 — intervention group
Group type: COMPARATOR
Intervention: Sieve
Number of subjects: 125
Study 22672173 — intervention group
Group type: COMPARATOR
Intervention: Sort
Number of subjects: 125
Study 20059474 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic medication review and counselling by a clinical pharmacist and clinical pharmacologist
Number of subjects: 100
Study 20059474 — intervention group
Group type: COMPARATOR
Intervention: Usual routine medication review in the ward
Number of subjects: 100
Study 20059474 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic medication review and counselling
Number of subjects: 100
Study 18724193 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Advisory Boards (CABs)
Number of subjects: 62
Study 15809366 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 9014
Study 15809366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 12182234 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud pack treatment
Number of subjects: 36
Study 12182234 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal bath treatment
Number of subjects: 36
Study 12182234 — intervention group
Group type: COMPARATOR
Intervention: Healthy untreated subjects (control)
Number of subjects: 36
Study 10726528 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical retreatment
Number of subjects: 95
Study 10726528 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical retreatment
Number of subjects: 95
Study 7579091 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 400 mg and a daily dose of 200 mg/day for 9 days (Group 1)
Number of subjects: 10
Study 7579091 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 200 mg and a maintenance dose of 100 mg/day for 9 days (Group 2)
Number of subjects: 10
Study 7579091 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 100 mg and a maintenance dose of 50 mg/day for 9 days (Group 3)
Number of subjects: 10
Study 7579091 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 200 mg and then 100 mg after each of four dialysis sessions (Group 4)
Number of subjects: 10
Study 1954179 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial chemotherapy followed by loco-regional treatment
Number of subjects: 272
Study 1954179 — intervention group
Group type: COMPARATOR
Intervention: Initial chemotherapy
Number of subjects: 272
Study 6800046 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 800 mg
Number of subjects: 60
Study 6800046 — intervention group
Group type: EXPERIMENTAL
Intervention: Azidocillin 750 mg
Number of subjects: 60
Study 6800046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6800046 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (Phenoxymethylpenicillin and Azidocillin)
Number of subjects: 60
Study 6800046 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin and Azidocillin
Number of subjects: 60
Study 31663391 — intervention group
Group type: EXPERIMENTAL
Intervention: People with tinnitus (PwT)
Number of subjects: 46
Study 31663391 — intervention group
Group type: COMPARATOR
Intervention: People without tinnitus (PnT)
Number of subjects: 46
Study 31135599 — intervention group
Group type: EXPERIMENTAL
Intervention: treadmill training and atDCS on Cz
Number of subjects: 30
Study 31135599 — intervention group
Group type: EXPERIMENTAL
Intervention: treadmill training and atDCS on Cb
Number of subjects: 30
Study 31135599 — intervention group
Group type: COMPARATOR
Intervention: treadmill training and sham tDCS on Cz
Number of subjects: 30
Study 29289933 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial central venous catheter (CVC)
Number of subjects: 12
Study 29289933 — intervention group
Group type: COMPARATOR
Intervention: Ordinary central venous catheter (CVC)
Number of subjects: 12
Study 25635593 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 5 μg/ml
Number of subjects: 104
Study 25635593 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 100 μg/ml
Number of subjects: 104
Study 25635593 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 104
Study 25635593 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 104
Study 25635593 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine and Phenylephrine
Number of subjects: 104
Study 23163915 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM-C/PG
Number of subjects: 40
Study 23163915 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 23163915 — intervention group
Group type: EXPERIMENTAL
Intervention: β-TCP
Number of subjects: 40
Study 23163915 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM-C/CM
Number of subjects: 40